Derek Meisner compensation by year
Acumen Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $141,705 | $455,663 |
| Bonus | $45,000 | $45,000 |
| Stock awards | $0 | $163,748 |
| Option awards | $1,039,500 | $559,944 |
| Non-equity incentive | $52,925 | $236,945 |
| Pension and deferred compensation | $0 | $0 |
| All other | $538 | $15,337 |
| Total | $1,279,668 | $1,476,637 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acumen Pharmaceuticals, Inc. DEF 14A filed April 22, 2024, accession 0001576885-24-000055, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Acumen Pharmaceuticals, Inc. filed document, accession 0001576885-24-000055. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 26,800 | $102,912 | — |
| Option | 154,688 | — | $6.08 |
| Option | 93,117 | — | $6.11 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Acumen Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
30 Form 4 lines since the FY2023 proxy (filed April 22, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-06 | Sale | 10b5-1 | 2,090 | $3.26 | 173,999 |
| 2026-03-06 | Exercise or conversion | 10b5-1 | 2,090 | $1.85 | 176,089 |
| 2026-03-06 | Exercise or conversion derivative | 10b5-1 | 2,090 | $0.00 | 71,048 |
| 2026-02-27 | Exercise or conversion | 10b5-1 | 9,406 | $1.85 | 183,405 |
| 2026-02-27 | Sale | 10b5-1 | 9,406 | $3.01 | 173,999 |
| 2026-02-27 | Exercise or conversion derivative | 10b5-1 | 9,406 | $0.00 | 73,138 |
| 2026-01-28 | Exercise or conversion | 10b5-1 | 2,671 | $1.85 | 176,670 |
| 2026-01-28 | Exercise or conversion derivative | 10b5-1 | 2,671 | $0.00 | 82,544 |
The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Acumen Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Daniel O'Connell | Chief Executive Officer | $3,930,011 |
| Matthew Zuga | Chief Financial Officer and Chief Business Officer | $1,606,289 |
| Derek Meisner · this page | Chief Legal Officer | $1,476,637 |
The full Acumen Pharmaceuticals compensation record
free company briefThis page is one person within Acumen Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Acumen Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.